Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gonadotropin releasing hormone agonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Gonadotropin releasing hormone agonist. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-003247-70 Sponsor Protocol Number: UZAPED1 Start Date*: 2007-10-29
    Sponsor Name:Belgian Study Group for Pediatric Endocrinology
    Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height.
    Medical condition: predicted short stature
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066333 Idiopathic short stature LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005208-20 Sponsor Protocol Number: 2019DEPO-TRIGGER001 Start Date*: 2022-08-10
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Depo-Trigger trial: GnRH agonist DEPOt TRIGGER for final oocyte maturation in breast cancer patients undergoing fertility preservation: a pilot study.
    Medical condition: Female patients with breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005255-18 Sponsor Protocol Number: 1216.19 Start Date*: 2006-07-03
    Sponsor Name:Boehringer Ingelheim UK Ltd
    Full Title: A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic...
    Medical condition: Advanced Metastatic Hormone Refractory Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005249-21 Sponsor Protocol Number: 1239.3 Start Date*: 2006-02-16
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer
    Medical condition: Chemo-naive hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005485-37 Sponsor Protocol Number: 20050147 Start Date*: 2006-06-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) BE (Completed) IE (Completed) SK (Completed) HU (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) LT (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002120-29 Sponsor Protocol Number: 0822-030 Start Date*: 2008-08-13
    Sponsor Name:Merck&Co.,Inc
    Full Title: A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer
    Medical condition: Prevention of bone metastases in men with prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001128-31 Sponsor Protocol Number: 13-23 Start Date*: 2014-09-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat...
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001105-81 Sponsor Protocol Number: ACT-CYC-300-2013-01 Start Date*: 2013-07-31
    Sponsor Name:Actavis Group PTC ehf.
    Full Title: Randomized Clinical Trial to Compare the Pregnancy Rates of Vaginally Applied Cyclogest® Pessary and Crinone® 8% Gel After In-vitro Fertilization
    Medical condition: Luteal phase support after IVF
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001805-40 Sponsor Protocol Number: PGL07-022 Start Date*: 2008-07-28
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist ...
    Medical condition: Uterine myomas are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asympt...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed) PL (Completed) DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004728-13 Sponsor Protocol Number: I3Y-MC-JPBL Start Date*: 2014-07-09
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced ...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Completed) FI (Completed) GR (Trial now transitioned) RO (Ongoing) DK (Completed) PL (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003007-38 Sponsor Protocol Number: 56021927PCR3003 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
    Medical condition: High- or very-high risk, localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BE (Trial now transitioned) NL (Completed) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020821-41 Sponsor Protocol Number: MDV3100-03 Start Date*: 2011-02-10
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W...
    Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001984-10 Sponsor Protocol Number: WO42312 Start Date*: 2020-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ES...
    Medical condition: Estrogen receptor (ER)-positive, HER2 negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002249-13 Sponsor Protocol Number: 3125001 Start Date*: 2019-02-04
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE...
    Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001721-13 Sponsor Protocol Number: TAK-013/EC-302 Start Date*: 2005-01-24
    Sponsor Name:Takeda Europe R&D Center Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001720-21 Sponsor Protocol Number: TAK-013/EC301 Start Date*: 2004-12-24
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-002301-10 Sponsor Protocol Number: I3Y-MC-JPEF Start Date*: 2022-02-15
    Sponsor Name:Eli Lilly and Company
    Full Title: postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advan...
    Medical condition: HR+, HER2-, Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004780-71 Sponsor Protocol Number: PROFERTIL Start Date*: Information not available in EudraCT
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil
    Medical condition: Breast Cancer Acute Leukemia Lymphomas (Hodgkin and non-Hodgkin) Sarcomas (Osteo, Soft tissue and Ewing)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001789-39 Sponsor Protocol Number: LAVA1207-001 Start Date*: 2021-07-13
    Sponsor Name:LAVA Therapeutics N.V.
    Full Title: A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cel...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 12:58:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA